Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Breast Cancer Therapeutics Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Mitotic Inhibitors
  • 1.4.3 Anti-Metabolites
  • 1.4.4 Hormone Receptor
  • 1.4.5 Aromatase Inhibitors
  • 1.4.6 HER2 Inhibitors
• 1.5 Market by Application
  • 1.5.1 Global Breast Cancer Therapeutics Market Share by Application (2014-2025)
  • 1.5.2 Hospital
  • 1.5.3 Research
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Breast Cancer Therapeutics Market Size
• 2.2 Breast Cancer Therapeutics Growth Trends by Regions
  • 2.2.1 Breast Cancer Therapeutics Market Size by Regions (2014-2025)
  • 2.2.2 Breast Cancer Therapeutics Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Breast Cancer Therapeutics Market Size by Manufacturers
  • 3.1.1 Global Breast Cancer Therapeutics Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Breast Cancer Therapeutics Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Breast Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
• 3.2 Breast Cancer Therapeutics Key Players Head office and Area Served
• 3.3 Key Players Breast Cancer Therapeutics Product/Solution/Service
• 3.4 Date of Enter into Breast Cancer Therapeutics Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Breast Cancer Therapeutics Market Size by Type (2014-2019)
• 4.2 Global Breast Cancer Therapeutics Market Size by Application (2014-2019)

5 United States

• 5.1 United States Breast Cancer Therapeutics Market Size (2014-2019)
• 5.2 Breast Cancer Therapeutics Key Players in United States
• 5.3 United States Breast Cancer Therapeutics Market Size by Type
• 5.4 United States Breast Cancer Therapeutics Market Size by Application

6 Europe

• 6.1 Europe Breast Cancer Therapeutics Market Size (2014-2019)
• 6.2 Breast Cancer Therapeutics Key Players in Europe
• 6.3 Europe Breast Cancer Therapeutics Market Size by Type
• 6.4 Europe Breast Cancer Therapeutics Market Size by Application

7 China

• 7.1 China Breast Cancer Therapeutics Market Size (2014-2019)
• 7.2 Breast Cancer Therapeutics Key Players in China
• 7.3 China Breast Cancer Therapeutics Market Size by Type
• 7.4 China Breast Cancer Therapeutics Market Size by Application

8 Japan

• 8.1 Japan Breast Cancer Therapeutics Market Size (2014-2019)
• 8.2 Breast Cancer Therapeutics Key Players in Japan
• 8.3 Japan Breast Cancer Therapeutics Market Size by Type
• 8.4 Japan Breast Cancer Therapeutics Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Breast Cancer Therapeutics Market Size (2014-2019)
• 9.2 Breast Cancer Therapeutics Key Players in Southeast Asia
• 9.3 Southeast Asia Breast Cancer Therapeutics Market Size by Type
• 9.4 Southeast Asia Breast Cancer Therapeutics Market Size by Application

10 India

• 10.1 India Breast Cancer Therapeutics Market Size (2014-2019)
• 10.2 Breast Cancer Therapeutics Key Players in India
• 10.3 India Breast Cancer Therapeutics Market Size by Type
• 10.4 India Breast Cancer Therapeutics Market Size by Application

11 Central & South America

• 11.1 Central & South America Breast Cancer Therapeutics Market Size (2014-2019)
• 11.2 Breast Cancer Therapeutics Key Players in Central & South America
• 11.3 Central & South America Breast Cancer Therapeutics Market Size by Type
• 11.4 Central & South America Breast Cancer Therapeutics Market Size by Application

12 International Players Profiles

• 12.1 Bayer HealthCare
  • 12.1.1 Bayer HealthCare Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Breast Cancer Therapeutics Introduction
  • 12.1.4 Bayer HealthCare Revenue in Breast Cancer Therapeutics Business (2014-2019)
  • 12.1.5 Bayer HealthCare Recent Development
• 12.2 Eli Lily
  • 12.2.1 Eli Lily Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Breast Cancer Therapeutics Introduction
  • 12.2.4 Eli Lily Revenue in Breast Cancer Therapeutics Business (2014-2019)
  • 12.2.5 Eli Lily Recent Development
• 12.3 Pfizer
  • 12.3.1 Pfizer Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Breast Cancer Therapeutics Introduction
  • 12.3.4 Pfizer Revenue in Breast Cancer Therapeutics Business (2014-2019)
  • 12.3.5 Pfizer Recent Development
• 12.4 Novartis
  • 12.4.1 Novartis Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Breast Cancer Therapeutics Introduction
  • 12.4.4 Novartis Revenue in Breast Cancer Therapeutics Business (2014-2019)
  • 12.4.5 Novartis Recent Development
• 12.5 Eisai
  • 12.5.1 Eisai Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Breast Cancer Therapeutics Introduction
  • 12.5.4 Eisai Revenue in Breast Cancer Therapeutics Business (2014-2019)
  • 12.5.5 Eisai Recent Development
• 12.6 Halozyme Therapeutics
  • 12.6.1 Halozyme Therapeutics Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Breast Cancer Therapeutics Introduction
  • 12.6.4 Halozyme Therapeutics Revenue in Breast Cancer Therapeutics Business (2014-2019)
  • 12.6.5 Halozyme Therapeutics Recent Development
• 12.7 Roche
  • 12.7.1 Roche Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Breast Cancer Therapeutics Introduction
  • 12.7.4 Roche Revenue in Breast Cancer Therapeutics Business (2014-2019)
  • 12.7.5 Roche Recent Development
• 12.8 Puma Biotechnology
  • 12.8.1 Puma Biotechnology Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Breast Cancer Therapeutics Introduction
  • 12.8.4 Puma Biotechnology Revenue in Breast Cancer Therapeutics Business (2014-2019)
  • 12.8.5 Puma Biotechnology Recent Development
• 12.9 Janssen Biotech
  • 12.9.1 Janssen Biotech Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Breast Cancer Therapeutics Introduction
  • 12.9.4 Janssen Biotech Revenue in Breast Cancer Therapeutics Business (2014-2019)
  • 12.9.5 Janssen Biotech Recent Development
• 12.10 AbbVie
  • 12.10.1 AbbVie Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Breast Cancer Therapeutics Introduction
  • 12.10.4 AbbVie Revenue in Breast Cancer Therapeutics Business (2014-2019)
  • 12.10.5 AbbVie Recent Development
• 12.11 BioMarin
• 12.12 Array BioPharma
• 12.13 Merck
• 12.14 Syndax
• 12.15 MacroGenics
• 12.16 ImmunoGen
• 12.17 Santen Pharma
• 12.18 Celgene
• 12.19 Oncothyreon
• 12.20 AstraZeneca
• 12.21 Sprint Bioscience
• 12.22 Genentech
• 12.23 Galena Biopharma
• 12.24 Lycera
• 12.25 CTI BioPharma

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer

Breast cancer is cancer that forms in the cells of the breasts.Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.
In 2018, the global Breast Cancer Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Breast Cancer Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Breast Cancer Therapeutics development in United States, Europe and China.

The key players covered in this study
Bayer HealthCare
Eli Lily
Pfizer
Novartis
Eisai
Halozyme Therapeutics
Roche
Puma Biotechnology
Janssen Biotech
AbbVie
BioMarin
Array BioPharma
Merck
Syndax
MacroGenics
ImmunoGen
Santen Pharma
Celgene
Oncothyreon
AstraZeneca
Sprint Bioscience
Genentech
Galena Biopharma
Lycera
CTI BioPharma

Market segment by Type, the product can be split into
Mitotic Inhibitors
Anti-Metabolites
Hormone Receptor
Aromatase Inhibitors
HER2 Inhibitors

Market segment by Application, split into
Hospital
Research

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Breast Cancer Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Breast Cancer Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Breast Cancer Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.